Trial Profile
A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Mild to Moderate Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Nebivolol (Primary)
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Bertek Pharmaceuticals
- 15 Jul 2015 New trial record
- 19 May 2015 Results presented at the 30th Annual Scientific Meeting of the American Society of Hypertension.